A comparative study on the clinical efficacy and pregnancy outcomes of methimazole and propylthiouracil in managing pregnancy complicated with hyperthyroidism

Abstract

 The objective of the study was to compare the clinical efficacy and pregnancy outcomes of methimazole and propylthiouracil in managing hyperthyroidism during pregnancy. This retrospective analysis included 100 pregnant women with hyperthyroidism, who were divided into two groups:  the methimazole group (Group A) and the propylthiouracil group  (Group B). Indicators such as thyroid function, liver function, pregnancy  outcomes, and newborn health were closely monitored. The results  revealed that both groups experienced a reduction in thyroid function  indicators, with Group B showing a more modest decrease. Group B  exhibited a higher incidence of liver injury but also achieved more full-term  pregnancies. There were no significant differences in adverse  reactions, miscarriage rates, or cesarean rates between the two groups.  Apgar scores were higher in Group B, while neonatal weights were  comparable. We conclude that propylthiouracil improved thyroid function  more substantially than methimazole although it was associated with a  higher risk of liver injury.